Honeywell International Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Honeywell International Inc trades at $207 (market cap $65.96B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: Honeywell International Inc is far larger — about 28.9× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Honeywell International Inc pays a 1.35% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| HON | SLS | |
|---|---|---|
Market Cap | $65.96B | $2.28B |
Volume | 2,009,898 | 3,128,960 |
Sector | Industrials | Health |
52-Week High | $248.79 | $15.46 |
52-Week Low | $188.14 | $1.39 |
Typical Hold Time | 90 Days | — |
Enterprise Value | $90.75B | $2.15B |
Dividend Yield | 1.35% | — |
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $206.6, down 2.95% on the day, with a bearish technical signal despite strong fundamentals including a low P/E of 8 and robust profitability margins. Recent quarterly earnings have consistently beaten expectations, and the company secured a significant $300 million refinery project with Dangote. Analyst consensus remains strongly bullish with a $259.25 price target, representing 25% upside potential from current levels.
The stock presents a compelling value opportunity given its discounted valuation metrics and consistent earnings outperformance, though investors face near-term technical headwinds and execution risks from the company's recent strategic transformation into a pure-play automation business following the spin-off of its aerospace and advanced materials divisions.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →